Industry Outlook and Trend Analysis
The Cystic Fibrosis (CF) Therapeutics Market was worth USD 2.15 billion in 2014 and is expected to reach approximately USD 22.46 billion by 2023, while registering itself at a compound annual growth rate (CAGR) of 29.79% during the forecast period. Expanding commonness of Cystic Fibrosis (CF) combined with rising rate of treatment is one of the key variables expected to push the interest for these therapeutics over the figure time frame. In addition, increment in R&D subsidizing by both private and open associations, rising number of activities attempted by philanthropic associations, and existence of ideal reimbursement policies are a portion of the essential elements anticipated that would drive the market in the coming few years. Moreover, expanding number of clinical trials to extend its objective patient base with the current medication portfolio is likewise among a portion of the drivers of this market.
Drug Class Outlook and Trend Analysis
On the basis of drug class, the market is sectioned into pancreatic enzyme supplements, bronchodilators, mucolytics, and CFTR modulators. The main factor in the treatment of CF is keeping up the function of the lung while controlling respiratory infection and clearing airways routes of mucus, dealing with the wholesome treatment, and controlling the complications. In 2016, CFTR modulators represented the biggest revenue with a share of roughly 47.3% inferable from the launch of new drug Orkambi. This drug is in charge of adjusting the capacity of defective protein caused by the CF gene.
Route of Administration Outlook and Trend Analysis
On the basis of route of administration, the market is sectioned into inhaled route and oral drugs. Oral route represented the biggest share of almost 63.7% out of 2016 inferable from the favourable circumstances related with its organization, for example, accommodation and simplicity of usage without the assistance of a medicinal services proficient.
Regional Outlook and Trend Analysis
Geographically, the market is portioned into Europe, North America, Asia Pacific, Latin America, and Middle East and Africa. North America represented the biggest income of USD 2,396.4 million in 2016. CF is most pervasive in North America as a large portion of the general population influenced with CF is of Caucasian plunge. Nonetheless, Asia Pacific is foreseen to be the quickest developing fragment.
The leading players in the market are Teva Pharmaceutical Industries, Merck & Co, AbbVie Inc, Alcresta Therapeutics Inc, Vertex Pharmaceuticals, ALAXIA, Gilead Sciences, Allergan, Roche Holding AG, AstraZeneca and Novartis. The major players in the market are profiled in detail in view of qualities, for example, company portfolio, business strategies, financial overview, recent developments, and share of the overall industry.
The Cystic Fibrosis (CF) Therapeutics Market is segmented as follows-
By Drug Class:
Pancreatic enzyme supplements
By Route of Administration:
Rest of Europe
Rest of Asia Pacific
Rest of the World
United Arab Emirates
Some of the key questions answered by the report are:
What was the market size in 2014 and forecast from 2015 to 2023?
What will be the industry market growth from 2015 to 2023?
What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
What are the major segments leading the market growth and why?
Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?